Founded in 2018 by biopharma veteran David Hung, M.D., Nuvation Bio develops and commercializes oncology medicines for difficult-to-treat cancers. The company’s portfolio includes the FDA-approved therapy IBTROZI® (taletrectinib) and investigational treatments supported by global clinical programs, with offices in the United States and China.
California Health & Safety Code §§ 119400-119402 Compliance Program
compliance_program
PhRMA Code Compliance Program
compliance_program